UNITY-NHL: Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma

Sponsor
TG Therapeutics, Inc. (Industry)
Overall Status
Terminated
CT.gov ID
NCT02793583
Collaborator
(none)
710
168
3
73.3
4.2
0.1

Study Details

Study Description

Brief Summary

Unity NHL - A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib with or without Bendamustine and Umbralisib alone in Patients with Previously Treated Non-Hodgkin's Lymphoma

Condition or Disease Intervention/Treatment Phase
Phase 2/Phase 3

Detailed Description

The purpose of this study is to evaluate the efficacy and safety of umbralisib monotherapy and the umbralisib + ublituximab (U2) combination in aggressive and indolent lymphomas and to also explore the U2 regimen in combination with bendamustine in the treatment of NHL (FL, SLL, MZL, DLBCL and MCL).

Study Design

Study Type:
Interventional
Actual Enrollment :
710 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkin's Lymphoma
Actual Study Start Date :
May 25, 2016
Actual Primary Completion Date :
May 31, 2022
Actual Study Completion Date :
Jul 4, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Umbralisib + Ublituximab

Umbralisib oral daily dose in combination with Ublituximab intravenous administration

Biological: Ublituximab
Other Names:
  • TG-1101
  • Drug: Umbralisib
    Other Names:
  • TGR-1202
  • Experimental: Umbralisib

    Umbralisib oral daily dose

    Drug: Umbralisib
    Other Names:
  • TGR-1202
  • Experimental: Umbralisib + Ublituximab + Bendamustine

    Umbralisib oral daily dose in combination with Ublituximab intravenous administration and Bendamustine intravenous administration

    Biological: Ublituximab
    Other Names:
  • TG-1101
  • Drug: Umbralisib
    Other Names:
  • TGR-1202
  • Biological: Bendamustine
    Other Names:
  • Treanda
  • Outcome Measures

    Primary Outcome Measures

    1. Overall Response Rate [Every 8-12 weeks, up to 2 years]

    Secondary Outcome Measures

    1. Progression-Free Survival [From date of randomization until the date of first documented progression, assessed up through 2 years]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Diagnosis of Non-Hodgkin's Lymphoma including Follicular, Mantle Cell Lymphoma and Marginal Zone Lymphoma

    • Relapsed or refractory to prior standard therapy and subjects who are not candidates for high-dose therapy or autologous stem cell transplant

    • MCL subjects with one or more lines of therapy including at least one BTK inhibitor (ibrutinib, acalabrutinib or zanibrutinib only)

    Exclusion Criteria:
    • Any major surgery, chemotherapy or immunotherapy within the last 21 days

    • Evidence of hepatitis B virus, hepatitis C virus or known HIV infection

    • Autologous hematologic stem cell transplant within 6 months of study entry. Prior Allogeneic hematologic stem cell transplant is excluded

    • Prior therapy with a PI3K delta inhibitor

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 TG Therapeutics Investigational Trial Site Birmingham Alabama United States 35243
    2 TG Therapeutics Investigational Trial Site Huntsville Alabama United States 35805
    3 TG Therapeutics Investigational Trial Site Chandler Arizona United States 85224
    4 TG Therapeutics Investigational Trial Site Tucson Arizona United States 85711
    5 TG Therapeutics Investigational Trial Site Tucson Arizona United States 85724
    6 TG Therapeutics Investigational Trial Site Los Angeles California United States 90095
    7 TG Therapeutics Investigational Trial Site Orange California United States 92868
    8 TG Therapeutics Investigational Trial Site San Diego California United States 90710
    9 TG Therapeutics Investigational Trial Site San Diego California United States 92108
    10 TG Therapeutics Investigational Trial Site Whittier California United States 90603
    11 TG Therapeutics Investigational Trial Site Aurora Colorado United States 80012
    12 TG Therapeutics Investigational Trial Site Denver Colorado United States 80218
    13 TG Therapeutics Investigational Trial Site Fort Collins Colorado United States 80528
    14 TG Therapeutics Investigational Trial Site Bridgeport Connecticut United States 06606
    15 TG Therapeutics Investigational Trial Site Newark Delaware United States 19713
    16 TG Therapeutics Investigational Trial Site Washington District of Columbia United States 20007
    17 TG Therapeutics Investigational Trial Site Boca Raton Florida United States 33486
    18 TG Therapeutics Investigational Trial Site Fort Myers Florida United States 33916
    19 TG Therapeutics Investigational Trial Site Gainesville Florida United States 32608
    20 TG Therapeutics Investigational Trial Site Jacksonville Florida United States 32204
    21 TG Therapeutics Investigational Trial Site Jacksonville Florida United States 32224
    22 TG Therapeutics Investigational Trial Site Jacksonville Florida United States 32256
    23 TG Therapeutics Investigational Trial Site Miami Florida United States 33176
    24 TG Therapeutics Investigational Trial Site Saint Petersburg Florida United States 33705
    25 TG Therapeutics Investigational Trial Site Tallahassee Florida United States 32308
    26 TG Therapeutics Investigational Trial Site Tampa Florida United States 33612
    27 TG Therapeutics Investigational Trial Site West Palm Beach Florida United States 33407
    28 TG Therapeutics Investigational Trial Site Albany Georgia United States 31701
    29 TG Therapeutics Investigational Trial Site Macon Georgia United States 31201
    30 TG Therapeutics Investigational Trial Site Marietta Georgia United States 30060
    31 TG Therapeutics Investigational Trial Site Chicago Illinois United States 60612
    32 TG Therapeutics Investigational Trial Site Chicago Illinois United States 60637
    33 TG Therapeutics Investigational Trial Site Decatur Illinois United States 62526
    34 TG Therapeutics Investigational Trial Site Evanston Illinois United States 60201
    35 TG Therapeutics Investigational Trial Site Harvey Illinois United States 60426
    36 TG Therapeutics Investigational Trial Site Maywood Illinois United States 60153
    37 TG Therapeutics Investigational Trial Site Niles Illinois United States 60714
    38 TG Therapeutics Investigational Trial Site Peoria Illinois United States 61615
    39 TG Therapeutics Investigational Trial Site Swansea Illinois United States 62226
    40 TG Therapeutics Investigational Trial Site Fort Wayne Indiana United States 46845
    41 TG Therapeutics Investigational Trial Site Indianapolis Indiana United States 46237
    42 TG Therapeutics Investigational Trial Site Westwood Kansas United States 66210
    43 TG Therapeutics Investigational Trial Site Louisville Kentucky United States 40207
    44 TG Therapeutics Investigational Trial Site Covington Louisiana United States 70433
    45 TG Therapeutics Investigational Trial Site Brewer Maine United States 04412
    46 TG Therapeutics Investigational Trial Site Baltimore Maryland United States 21201
    47 TG Therapeutics Investigational Trial Site Bethesda Maryland United States 20817
    48 TG Therapeutics Investigational Trial Site Columbia Maryland United States 21044
    49 TG Therapeutics Investigational Trial Site Towson Maryland United States 21204
    50 TG Therapeutics Investigational Trial Site Ann Arbor Michigan United States 48109
    51 TG Therapeutics Investigational Trial Site Duluth Minnesota United States 55805
    52 TG Therapeutics Investigational Trial Site Saint Louis Park Minnesota United States 55416
    53 TG Therapeutics Investigational Trial Site Columbia Missouri United States 65212
    54 TG Therapeutics Investigational Trial Site Kansas City Missouri United States 64132
    55 TG Therapeutics Investigational Trial Site Saint Louis Missouri United States 63110
    56 TG Therapeutics Investigational Trial Site Billings Montana United States 59102
    57 TG Therapeutics Investigational Trial Site Lincoln Nebraska United States 68510
    58 TG Therapeutics Investigational Trial Site Omaha Nebraska United States 68130
    59 TG Therapeutics Investigational Trial Site Lebanon New Hampshire United States 03756
    60 TG Therapeutics Investigational Trial Site Hackensack New Jersey United States 07601
    61 TG Therapeutics Investigational Trial Site Morristown New Jersey United States 07962
    62 TG Therapeutics Investigational Trial Site Mount Holly New Jersey United States 08060
    63 TG Therapeutics Investigational Trial Site Farmington New Mexico United States 87401
    64 TG Therapeutics Investigational Trial Site Bronx New York United States 10467
    65 TG Therapeutics Investigational Trial Site Buffalo New York United States 14263
    66 TG Therapeutics Investigational Trial Site New York New York United States 10019
    67 TG Therapeutics Investigational Trial Site Syracuse New York United States 13210
    68 TG Therapeutics Investigational Trial Site Charlotte North Carolina United States 28201
    69 TG Therapeutics Investigational Trial Site Durham North Carolina United States 27705
    70 TG Therapeutics Investigational Trial Site Hickory North Carolina United States 28602
    71 TG Therapeutics Investigational Trial Site Kinston North Carolina United States 28501
    72 TG Therapeutics Investigational Trial Site Raleigh North Carolina United States 27607
    73 TG Therapeutics Investigational Trial Site Washington North Carolina United States 27889
    74 TG Therapeutics Investigational Trial Site Canton Ohio United States 44718
    75 TG Therapeutics Investigational Trial Site Cincinnati Ohio United States 45220
    76 TG Therapeutics Investigational Trial Site Cincinnati Ohio United States 45242
    77 TG Therapeutics Investigational Trial Site Cleveland Ohio United States 44106
    78 TG Therapeutics Investigational Trial Site Columbus Ohio United States 43219
    79 TG Therapeutics Investigational Trial Site Toledo Ohio United States 43623
    80 TG Therapeutics Investigational Trial Site Portland Oregon United States 97213
    81 TG Therapeutics Investigational Trial Site Portland Oregon United States 97227
    82 TG Therapeutics Investigational Trial Site Springfield Oregon United States 97477
    83 TG Therapeutics Investigational Trial Site Camp Hill Pennsylvania United States 17011
    84 TG Therapeutics Investigational Trial Site Philadelphia Pennsylvania United States 19106
    85 TG Therapeutics Investigational Trial Site Providence Rhode Island United States 02906
    86 TG Therapeutics Investigational Trial Site Greenville South Carolina United States 29615
    87 TG Therapeutics Investigational Trial Site Sioux Falls South Dakota United States 57105
    88 TG Therapeutics Investigational Trial Site Watertown South Dakota United States 57201
    89 TG Therapeutics Investigational Trial Site Chattanooga Tennessee United States 37404
    90 TG Therapeutics Investigational Trial Site Kingsport Tennessee United States 37660
    91 TG Therapeutics Investigational Trial Site Knoxville Tennessee United States 37916
    92 TG Therapeutics Investigational Trial Site Memphis Tennessee United States 38120
    93 TG Therapeutics Investigational Trial Site Austin Texas United States 78705
    94 TG Therapeutics Investigational Trial Site Dallas Texas United States 75390
    95 TG Therapeutics Investigational Trial Site Fort Sam Houston Texas United States 78234
    96 TG Therapeutics Investigational Trial Site Houston Texas United States 77030
    97 TG Therapeutics Investigational Trial Site San Antonio Texas United States 78130
    98 TG Therapeutics Investigational Trial Site San Antonio Texas United States 78217
    99 TG Therapeutics Investigational Trial Site San Antonio Texas United States 78229
    100 TG Therapeutics Investigational Trial Site Tyler Texas United States 75702
    101 TG Therapeutics Investigational Trial Site Ogden Utah United States 84403
    102 TG Therapeutics Investigational Trial Site Blacksburg Virginia United States 24060
    103 TG Therapeutics Investigational Trial Site Newport News Virginia United States 23601
    104 TG Therapeutics Investigational Trial Site Olympia Washington United States 98502
    105 TG Therapeutics Investigational Trial Site Seattle Washington United States 98104
    106 TG Therapeutics Investigational Trial Site Seattle Washington United States 98108
    107 TG Therapeutics Investigational Trial Site Seattle Washington United States 98109
    108 TG Therapeutics Investigational Trial Site Spokane Washington United States 99216
    109 TG Therapeutics Investigational Trial Site Vancouver Washington United States 97277
    110 TG Therapeutics Investigational Trial Site Madison Wisconsin United States 53792
    111 TG Therapeutics Investigational Trial Site Wauwatosa Wisconsin United States 53226
    112 TG Therapeutics Investigational Trial Site Gosford New South Wales Australia 02250
    113 TG Therapeutics Investigational Trial Site Wahroonga New South Wales Australia 02076
    114 TG Therapeutics Investigational Trial Site Benowa Queensland Australia 04217
    115 TG Therapeutics Investigational Trial Site South Brisbane Queensland Australia 04101
    116 TG Therapeutics Investigational Trial Site Adelaide South Australia Australia 05000
    117 TG Therapeutics Investigational Trial Site Heidelberg Victoria Australia 03084
    118 TG Therapeutics Investigational Trial Site Nedlands Western Australia Australia 06009
    119 TG Therapeutics Investigational Trial Site Netherlands Western Australia Australia 06009
    120 TG Therapeutics Investigational Trial Site Gosford Australia 2076
    121 TG Therapeutics Investigational Trial Site Ashkelon Israel 7830604
    122 TG Therapeutics Investigational Trial Site Be'er Sheva Israel 8410101
    123 TG Therapeutics Investigational Trial Site Haifa Israel 91031
    124 TG Therapeutics Investigational Trial Site Jerusalem Israel 9112001
    125 TG Therapeutics Investigational Trial Site Nahariya Israel 2210001
    126 TG Therapeutics Investigational Trial Site Petah Tikva Israel 49100
    127 TG Therapeutics Investigational Trial Site Tel Aviv Israel 64239
    128 TG Therapeutics Investigational Trial Site Tel Aviv Israel 6971028
    129 TG Therapeutics Investigational Trial Site Bologna Italy 40138
    130 TG Therapeutics Investigational Trial Site Ferrara Italy 44020
    131 TG Therapeutics Investigational Trial Site Milan Italy 20132
    132 TG Therapeutics Investigational Trial Site Milan Italy 20141
    133 TG Therapeutics Investigational Trial Site Rome Italy 00161
    134 TG Therapeutics Investigational Trial Site Torino Italy 10126
    135 TG Therapeutics Investigational Trial Site Busan Korea, Republic of 47392
    136 TG Therapeutics Investigational Trial Site Busan Korea, Republic of 49241
    137 TG Therapeutics Investigational Trial Site Gyeonggi-do Korea, Republic of 13620
    138 TG Therapeutics Investigational Trial Site Incheon Korea, Republic of 21565
    139 TG Therapeutics Investigational Trial Site Seoul Korea, Republic of 03080
    140 TG Therapeutics Investigational Trial Site Seoul Korea, Republic of 06351
    141 TG Therapeutics Investigational Trial Site Seoul Korea, Republic of 06591
    142 TG Therapeutics Investigational Trial Site Chorzów Poland 41-500
    143 TG Therapeutics Investigational Trial Site Gdynia Poland 81-519
    144 TG Therapeutics Investigational Trial Site Kraków Poland 30-510
    145 TG Therapeutics Investigational Trial Site Lublin Poland 20-090
    146 TG Therapeutics Investigational Trial Site Słupsk Poland 76-200
    147 TG Therapeutics Investigational Trial Site Warszawa Poland 02-106
    148 TG Therapeutics Investigational Trial Site Warszawa Poland 02-781
    149 TG Therapeutics Investigational Trial Site Wrocław Poland 50-367
    150 TG Therapeutics Investigational Trial Site Łódź Poland 93-513
    151 TG Therapeutics Investigational Trial Site Bratislava Slovakia 81250
    152 TG Therapeutics Investigational Trial Site Bratislava Slovakia 83310
    153 TG Therapeutics Investigational Trial Site Košice Slovakia 04191
    154 TG Therapeutics Investigational Trial Site Poprad Slovakia 05801
    155 TG Therapeutics Investigational Trial Site Barcelona Spain 08035
    156 TG Therapeutics Investigational Trial Site Barcelona Spain 08041
    157 TG Therapeutics Investigational Trial Site Madrid Spain 28041
    158 TG Therapeutics Investigational Trial Site Madrid Spain 28222
    159 TG Therapeutics Investigational Trial Site Salisbury Spain 37007
    160 TG Therapeutics Investigational Trial Site Valencia Spain 46010
    161 TG Therapeutics Investigational Trial Site Cambridge United Kingdom CB2-0QQ
    162 TG Therapeutics Investigational Trial Site Denmark Hill United Kingdom SE5-9RS
    163 TG Therapeutics Investigational Trial Site Leeds United Kingdom LS97TF
    164 TG Therapeutics Investigational Trial Site Liverpool United Kingdom L7-8XP
    165 TG Therapeutics Investigational Trial Site London United Kingdom EC1A-7BE
    166 TG Therapeutics Investigational Trial Site London United Kingdom SW170QT
    167 TG Therapeutics Investigational Trial Site Oxford United Kingdom OX37LE
    168 TG Therapeutics Investigational Trial Site Plymouth United Kingdom PL68DH

    Sponsors and Collaborators

    • TG Therapeutics, Inc.

    Investigators

    • Study Chair: Owen A O'Connor, MD, PhD, Columbia University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    TG Therapeutics, Inc.
    ClinicalTrials.gov Identifier:
    NCT02793583
    Other Study ID Numbers:
    • UTX-TGR-205
    First Posted:
    Jun 8, 2016
    Last Update Posted:
    Jul 21, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Keywords provided by TG Therapeutics, Inc.
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 21, 2022